26 months mPFS in phase 1/2, Northwest Biotherapeutics is to brain cancers what Juno Therapeutics is to leukemia.
Such an impressive number that unless its fake and we believe that the company is fraudulent there is no way to realistically fail primary endpoint in current trial, either that or the fact that they hired cross blinded radiologists to determine progression are the main risks.
We are close to finish line and the stock price finally found a floor, let's find a bit of patience and not forget that any delay means that patients are living longer thanks to this technology.
Best wishes,
Docinvestor
Market Data 
Markets 
AI
